Novocure to Report Third Quarter 2016 Financial Results

September 30, 2017 12:00 AM Eastern Standard Time ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss …

CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma

Guidelines provide a framework for using the NovoTAL System to optimize Tumor Treating Fields intensity in Optune patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that CNS Oncology published Tumor Treating Fields (TTFields) treatment planning and patient follow-up guidelines, providing a standardized resource for the use of the NovoTAL System to optimize TTFields intensity in …

Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Executive Chairman William Doyle will present at the New York Academy of Sciences’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms on Friday, Sept. 23, 2016. Mr. Doyle’s presentation “Tumor Treating Fields – A Novel Cancer Therapy Utilizing Alternating Electric Fields” will focus …

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that two independent institutions published scientific research on Tumor Treating Fields (TTFields), representing increasing external interest from the scientific community in Novocure’s innovative, proprietary therapy. The published data support Novocure’s existing body of …

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide ST. HELIER, JERSEY–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that long-term survival analysis of the full 695 patient dataset from the phase 3 pivotal EF-14 trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) …

International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo

Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 ST. HELIER, JERSEY–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data showing Tumor Treating Fields (TTFields) in combination with paclitaxel is therapeutically effective against ovarian cancer cells in vitro and in vivo has been published …